ed by Dr. S. Menzel, University of Oxford, England. The test correctly identified the six mutated alleles in the twelve samples with no false negatives or positives. We further screened our current material of 19 Norwegian MODY probands for the hot spot mutation. Including N1, three families were positive, indicating a prevalence in Norway of P291fsinsC similar to that observed in other populations [2, 3, 5] .
In conclusion, we believe that the test presented here is well suited for pre-screening larger patient materials of Caucasian origin for the MODY3 insertion mutation in codon 291. Because of the inherent difficulty in replicating the hot spot region with high fidelity, the choice of DNA polymerase and cycling/buffer conditions is, however, crucial for a successful test. Finally, it should be noted that the heterozygous restriction pattern shown in Figure 1 T-Cell markers in Type I diabetes: progress, prospects and realistic expectations
Dear Sir, Much of our knowledge of the natural course of human Type I (insulin dependent) diabetes mellitus derives from investigations of the humoral (i. e. autoantibody) compartment of the immune system. This aspect of immunological investigation has seen considerable progress in laboratory standardisation of assays and practical application in the form of tests that predict future cases of Type I diabetes. This progress has been achieved through the hard work and commitment of numerous laboratories throughout the world over the last 15 years and owes much to the support of organisations such as the Immunology of Diabetes Society and the Juvenile Diabetes Foundation. An abundant body of evidence suggests, however, that it is the cellular rather than the humoral limb of the immune system that is actively involved in the destruction of pancreatic beta cells. Therefore increasing attention on T-cells seems to be required to characterise the preclinical state, monitor intervention strategies and provide surrogate end points for clinical trials. For these reasons, a need exists for assays that accurately measure the effector and regulatory activities of T-cells. Unfortunately, attempts to bring humoral immune system-like standardisation in terms of laboratory quality assurance applications (e. g., interlaboratory and intralaboratory reproducibility, specificity, sensitivity, etc.) to the measurement of cellular immune system markers of Type I diabetes are still in their infan- Among such issues is a frank recognition of the multiple and sometimes unique limitations associated with human Tcell assays. The most obvious limitation is the inability (for ethical and practical reasons) to conduct experiments in vivo. Tcells mediating an in vivo effect in the disease process would be expected to be concentrated at the site of the inflammatory lesion (e. g. the pancreatic islet) or draining lymph node rather than freely circulating in the blood (with levels in the blood as low as 10 ±5 to 10 ±6 ), in contrast to autoantibodies. Thus, assays of human T-cell function rely on the ability of the in vitro systems to mimic in vivo situations or at least to detect cells that have been activated in vivo. Unfortunately, the in vitro manipulation of T-cells can lead to misleading artefacts. For example, the phenotype and function of T-cells can be influenced by factors such as isolation procedures, antigen concentration, source of serum used for cell culture and cytokine concentrations within the culture. In addition, unlike autoantibody molecules in serum, T-cells cannot be frozen and thawed for the purposes of standardisation without the expectation that their functional capabilities will be considerably altered during the process. In addition to these factors, simple enumeration of Tcells before and after antigen stimulation is in many cases not mathematically feasible because the cells that are responding represent only a small percentage (i. e. less than 10 in 100 000) of the total cell population. Finally, there can be little doubt that the purity of antigen preparations needed for detection of autoreactive T-cells is far greater than that required for autoantibodies.
Clearly, investigators covet the ability to use a T-cell response of a certain type and magnitude for the purpose of providing a surrogate marker for clinical or diagnostic benefit or both. Trials for the prevention of Type I diabetes are long, costly and usually are limited in their near-exclusive use of end points involving clinical effect (e. g. prolonged honeymoon, prevention of overt Type I diabetes). Our workshops have now indicated that specific issues must be addressed for measurement of T-cell responses to be accepted as true surrogate markers for Type I diabetes. In particular, there is a need to develop and evaluate truly quantitative assays that can be carried out reproducibly in different laboratories. Highly purified preparations of beta-cell autoantigens (e. g. glutamate decarboxylase, IA-2/ICA512, proinsulin) are available to investigators wishing to evaluate new methods for surrogate markers involving T-cells (contact mark.peakman@kcl.ac.uk). The recent advent of tetramer analysis and improvements in the ELIspot system are just two examples of possible approaches. In addition, a clear understanding of the T-cell subsets that are involved in various disease processes is likely to be beneficial. In the near future, due to the high potential relevance of such data to disease mechanisms, we will probably see the continued development of robust and reliable quantitative assays of T-cell function that can be used to analyse relatively large numbers of samples. A combination of these technological advancements, committed laboratories and continued support from relevant organisations is likely to transform the measurement of cellular immunity, leading to a major increase in enthusiasm for this important field of investigation in Type I diabetes. 
